Literature DB >> 19018971

Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies.

Gianpiero Gravante1, Giuseppe Sconocchia, Seok Ling Ong, Ashley R Dennison, David M Lloyd.   

Abstract

Ablation of liver tissue produces in situ tumoural antigens and elicits specific immune responses. The aim of this review is to examine the available data about the local and systemic responses produced and to compare differences between the methods available. A literature search was undertaken for all papers focusing on immune responses following ablative therapy of the liver, including experimental and clinical studies. Following ablative procedures, the cellular response is elicited by the presentation of antigens by dendritic cells to specific CD4(+) T cells, which in turn stimulate natural killer or CD8(+) cytotoxic cells. The local release of intracellular debris activates Kupffer cells to produce cytokines, which, in the immediate vicinity, activate monocytes/macrophages or specific T cells that respond and produce systemic reactions such as fever, thrombocytopaenia or shock. The immune responses elicited by cryotherapy, both cellular and cytokine, seem far greater than those produced by radiofrequency or microwave ablation, probably as a consequence of the peculiar mechanism of cell death of the former (disruptive necrosis). This mechanism is considered central to the pathogenesis of cryoshock. Ablative techniques stimulate the immune system and provide an easy way to achieve in vivo vaccination against tumoural antigens. Immunomodulatory approaches have the potential to augment the initial immune stimulation and this combined approach could pave the way to a more selective and specific method of treating liver tumours.

Entities:  

Mesh:

Year:  2008        PMID: 19018971     DOI: 10.1111/j.1478-3231.2008.01915.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  23 in total

1.  Large volume hepatic microwave ablation elicits fewer pulmonary changes than radiofrequency or cryotherapy.

Authors:  Fateh Ahmad; Gianpiero Gravante; Neil Bhardwaj; Andrew Strickland; Rizwan Basit; Kevin West; Roberto Sorge; Ashley R Dennison; David M Lloyd
Journal:  J Gastrointest Surg       Date:  2010-07-30       Impact factor: 3.452

Review 2.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

3.  Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experience.

Authors:  Jason B Hartman; Nicholas Bhojwani; David J Corn; Matthew M Cooney; John Haaga; Lee Ponsky; Robert Abouassaly; Akshay Paspulati; J David Prologo
Journal:  J Vasc Interv Radiol       Date:  2014-03-18       Impact factor: 3.464

Review 4.  Local treatment of oligometastatic disease: current role.

Authors:  Moritz T Winkelmann; Stephan Clasen; Philippe L Pereira; Rüdiger Hoffmann
Journal:  Br J Radiol       Date:  2019-06-06       Impact factor: 3.039

Review 5.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 6.  Therapeutic options for intermediate-advanced hepatocellular carcinoma.

Authors:  Zong-Ming Zhang; Jin-Xing Guo; Zi-Chao Zhang; Nan Jiang; Zhen-Ya Zhang; Li-Jie Pan
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

7.  The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death.

Authors:  Christian Beyer; Nancy A Stearns; Adreas Giessl; Jörg H W Distler; Georg Schett; David S Pisetsky
Journal:  Innate Immun       Date:  2012-02-16       Impact factor: 2.680

Review 8.  Focused ultrasound: tumour ablation and its potential to enhance immunological therapy to cancer.

Authors:  Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi
Journal:  Br J Radiol       Date:  2018-01-17       Impact factor: 3.039

Review 9.  Immunomodulation in hepatocellular cancer.

Authors:  Sunyoung Lee; Matthew Loecher; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2018-02

10.  Enhancing therapeutic efficacy through designed aggregation of nanoparticles.

Authors:  Tanmoy Sadhukha; Timothy S Wiedmann; Jayanth Panyam
Journal:  Biomaterials       Date:  2014-06-16       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.